Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: J Thorac Oncol. 2019 Mar 1;14(5):802–815. doi: 10.1016/j.jtho.2018.12.038

FIGURE 3. Characterization of an EGFR mutant cell line with PJA2/BRAF fusion.

FIGURE 3.

A. Expression of PJA2/BRAF in a patient-derived cell line, MSK-LX138cl, and xenograft tissue. B. Sanger sequencing of PCR product confirming a fusion between PJA2 exon 7 and BRAF exon 11. C. MSK-LX138cl cells were treated with 0.5 osimertinib for 1 h, whole-cell extracts prepared and then lysates were subjected to immunoblotting. Results represent 3 independent experiments. D-E. MSK-LX138cl cells were plated at a density 7,500/well in a 96-well plates, treated with EGFR (D) or BRAF (E) inhibitors. IC50 values for growth inhibition were determined by nonlinear regression analysis using Graphpad Prism software. F. 50,000 MSK-LX138cl cells/well were plated in 96-well plates, the following day they were treated with 0.1 or 1 μM of the indicated agents or a combination of osimertinib, and trametinib. Caspase 3/7 activity was determined 48 h later. Results represent the mean ± SD of 2 experiments.